Share

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT)

Project objectives

PFS, OS, ORR.

Start and end date
2023 - Ongoing

Project Manager
Prof. Angioli Roberto - Coordinator

Coordinating institution of the project
UCBM
2023© Università Campus Bio-Medico di Roma, Via Álvaro del Portillo, 21 - 00128 Rome, Tel. +39 06.22541.1, Fax +39 06.22541.456, VAT number: 048 020 51 005, Fiscal Code: 97087620585
QUICK LINKS
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
magnifiercrossmenuchevron-downchevron-leftchevron-right